Clinical Trials Arena on MSN

Ascletis receives FDA approval for diabetes mellitus clinical trial of ASC30

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin ...
MPR

Obexelimab Significantly Reduces Flare Risk in IgG4-Related Disease

Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.

Nanjing Delova Announces Statistically Significant and Clinically Meaningful Results From Two Phase 3 Trials of QP-6211 for the Treatment of Postoperative Pain

Nanjing Delova Biotech Co., Ltd. ("Delova") today announced positive results from two pivotal Phase 3 clinical trials ...
The Manila Times

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single ...
TipRanks on MSN

Corvus Pharmaceuticals confirms plans to announce results of Soquelitinib trial

Corvus Pharmaceuticals (CRVS) confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase ...

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh ...

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...